Bio-Rad Laboratories Inc. (BIO) Stock

Bio-Rad Laboratories Inc. trades at a P/E ratio of 26.88, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 35.84 is higher than the current P/E, indicating analysts expect earnings to decline over the next year. The PEG ratio of 1.19 indicates reasonable value when growth is considered.

With a beta of 0.91, Bio-Rad Laboratories Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.13 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Bio-Rad Laboratories Inc. achieves a profit margin of 12.50%, meaning it retains $12.50 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 12.20% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 4.59% and ROA at 1.59%, the company achieves moderate returns on invested capital.

Bio-Rad Laboratories Inc.'s revenue grew by 2.10% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 83.00% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against LABORATORY ANALYTICAL INSTRUMENTS industry averages for proper context.

Bio-Rad Laboratories Inc. has a market capitalization of $7.86B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 21.99M shares outstanding, the company's ownership is relatively concentrated. As a participant in the LABORATORY ANALYTICAL INSTRUMENTS industry, it competes with other firms in this sector.

Bio-Rad Laboratories Inc.'s book value per share is $263.42, while the current stock price is $280.29, resulting in a price-to-book (P/B) ratio of 1.06. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

6 analysts cover BIO with 67% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $326.50 implies 16.5% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:2 Strong Buy, 2 Buy, 2 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.